Skeletal muscle-targeted peptide MSP – Other Categories

Gene therapy is potentially an ideal treatment for muscle tissue myopathies but targeting remains an issue. The large volume of muscle in the body versus the requirement for tissue-specificity is of particular concern. This heptapeptide has been shown to preferentially bind skeletal myofibers and thus can be used to study targeting of peptide/gene-delivery to muscle tissue. Research into gene therapy of Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) has been of particular interest with muscle targeting peptides. This product already shows ideal placement to continue that research to overcome some of these issues.